| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DECR2 |
| Uniprot No | Q9NUI1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-292aa |
| 氨基酸序列 | MAQPPPDVEGDDCLPAYRHLFCPDLLRDKVAFITGGGSGIGFRIAEIFMRHGCHTVIASRSLPRVLTAARKLAGATGRRCLPLSMDVRAPPAVMAAVDQALKEFGRIDILINCAAGNFLCPAGALSFNAFKTVMDIDTSGTFNVSRVLYEKFFRDHGGVIVNITATLGNRGQALQVHAGSAKAAVDAMTRHLAVEWGPQNIRVNSLAPGPISGTEGLRRLGGPQASLSTKVTASPLQRLGNKTEIAHSVLYLASPLASYVTGAVLVADGGAWLTFPNGVKGLPDFASFSAKL |
| 分子量 | 57.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人DECR2蛋白的3篇文献摘要示例：
1. **"Cloning, Expression, and Functional Characterization of Human DECR2 in Fatty Acid Metabolism"**
*Authors: Zhang et al. (2020)*
摘要：报道了人DECR2基因的克隆及在大肠杆菌中的重组表达，验证了其作为2.4-二烯酰-CoA还原酶在细胞线粒体多不饱和脂肪酸β-氧化中的催化活性，并优化了纯化条件以提高蛋白稳定性。
2. **"Structural Insights into Human DECR2 via X-ray Crystallography and Substrate Specificity Analysis"**
*Authors: Smith et al. (2018)*
摘要：通过X射线晶体学解析了重组人DECR2的三维结构(分辨率2.1Å)，结合酶动力学实验揭示了底物结合口袋的关键氨基酸残基及其对长链脂肪酸的催化偏好性。
3. **"DECR2 Deficiency Links Mitochondrial Dysfunction to Neurodegenerative Disorders"**
*Authors: Brown & Lee (2019)*
摘要：利用CRISPR技术构建DECR2敲除细胞模型，发现其缺失导致线粒体中脂质代谢异常和活性氧积累，提示DECR2在神经退行性疾病中的潜在调控作用。
4. **"High-Throughput Screening of DECR2 Inhibitors for Anticancer Drug Development"**
*Authors: García-Sánchez et al. (2021)*
摘要：基于重组DECR2蛋白建立高通量筛选平台，筛选出小分子抑制剂并验证其通过干扰脂肪酸代谢抑制癌细胞的增殖，为靶向DECR2的肿瘤治疗提供依据。
(注：以上文献为虚拟示例，实际研究中请以真实发表的论文为准。)
Recombinant human DECR2 (short for 2.4-dienoyl-CoA reductase 2), also known as HSD17B4. is a peroxisomal enzyme encoded by the HSD17B4 gene. It belongs to the 17β-hydroxysteroid dehydrogenase family and plays a critical role in fatty acid β-oxidation, specifically in the degradation of unsaturated fatty acids. DECR2 catalyzes the reduction of 2.4-dienoyl-CoA to trans-3-enoyl-CoA, a key step in the β-oxidation of polyunsaturated fatty acids (PUFAs). This enzymatic activity is essential for maintaining lipid homeostasis and energy production, particularly in tissues with high metabolic demands like the liver, heart, and brain.
The recombinant form of DECR2 is produced using expression systems such as E. coli or mammalian cells, enabling large-scale purification for research and therapeutic applications. Its study has shed light on metabolic disorders linked to defective fatty acid oxidation, including Zellweger syndrome and neurodegenerative diseases. Additionally, DECR2’s role in cellular redox balance and its potential involvement in cancer metabolism have sparked interest in its use as a biomarker or therapeutic target. Structural and functional analyses of recombinant DECR2 aid in elucidating substrate specificity and designing inhibitors, advancing metabolic disease research and drug development.
×
